Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Income from Continuing Operations (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Income from Continuing Operations for 9 consecutive years, with 11235000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 50.73% to 11235000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 4336000.0, a 93.75% increase, with the full-year FY2025 number at 5345000.0, up 92.3% from a year prior.
  • Income from Continuing Operations was 11235000.0 for Q4 2025 at Akebia Therapeutics, down from 540000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 29038000.0 in Q2 2022 to a low of 84304000.0 in Q2 2021.
  • A 5-year average of 25328750.0 and a median of 16237000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 134.44% in 2022, then tumbled 3814.01% in 2024.
  • Akebia Therapeutics' Income from Continuing Operations stood at 70422000.0 in 2021, then skyrocketed by 90.76% to 6504000.0 in 2022, then skyrocketed by 109.44% to 614000.0 in 2023, then crashed by 3814.01% to 22804000.0 in 2024, then soared by 50.73% to 11235000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Income from Continuing Operations are 11235000.0 (Q4 2025), 540000.0 (Q3 2025), and 247000.0 (Q2 2025).